Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients with Chronic Hepatitis B

Key Inclusion Criteria:

• Male or women of non-child bearing potential

• BMI 18.0 to 35.0

• Good overall health deemed by the study Investigator

• CHB infection documented at least 12 months prior to screening

• HBeAg-negative CHB

• Must be virologically suppressed on current NA treatment

Key Exclusion Criteria:

• No history of cirrhosis of the liver

• No current infections of Hepatitis A, D, and E, human immunodeficiency virus (type 1and 2), and no history of or current hepatitis C. In addition, no other activeinfections deemed clinically relevant.

• No signs of hepatocellular carcinoma

• Not received an organ transplant

• No malignancy within 5 years of screening, except for specific cancers that arecured by surgical resection (e.g., basal cell skin cancer)

• No investigational agent received within 6 months of screening